Drug intelligence / Profile preview

HM12470

Development stage
Phase 1
Lead developer
Hanmi Pharmaceutical
Modality
Small Molecules, Recombinant Proteins and Enzymes, Peptides
Administration
Subcutaneous
01

Overview

HM12470 is a novel long-acting insulin analogue developed by Hanmi Pharmaceutical. It is designed for once-weekly subcutaneous administration to provide steady basal insulin levels for the treatment of diabetes mellitus. The drug features a substantially prolonged pharmacokinetic and pharmacodynamic profile compared to regular insulin and does not increase mitogenic potency. Preclinical studies indicate that it maintains metabolic potency after long-term stimulation and shows improved recovery of insulin signaling under chronic exposure conditions. Its mechanism of action includes stimulation of ornithine decarboxylase, phosphokinase, and protein tyrosine kinase pathways[1][2][7]. Clinical development has focused on type 1 and type 2 diabetes mellitus[1][3][10].

Other names
Insulin 115Insulin115Insulin-115
02

Targets

INSR (Insulin receptor)ODC1 (Ornithine decarboxylase)PTK (Protein-Tyrosine Kinase)

Beyond the preview

Go deeper on HM12470.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HM12470.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call